Oscillometry to support clinical assessment in asthmatic preschoolers: Real-life impact
- PMID: 36754219
- DOI: 10.1016/j.rmed.2023.107148
Oscillometry to support clinical assessment in asthmatic preschoolers: Real-life impact
Abstract
In preschoolers, asthma control is assessed clinically using history and physical examination. In certain centres, oscillometry is used to support clinical assessment; yet its clinical utility for asthma management remains to be quantified. The objectives were to determine if oscillometry, as adjunct to clinical assessment, influences asthma assessment, management and control, compared to clinical assessment alone in preschoolers. We conducted a cross-sectional study in children aged 3-5 years with a confirmed asthma diagnosis. Oscillometry-tested preschoolers were matched by propensity score to untested children. The co-primary outcomes, the likelihood of a persistent asthma phenotype and a maintenance therapy prescription at the index visit, were examined by multivariable logistic regression. Asthma control over the next year was examined by cumulative logistic regression in the nested retrospective cohort with available drug claim data. The cohort comprised 726 (249 oscillometry-tested; 477 untested) children with 57.4% male (median age: 4.6 years). Propensity score matching resulted in comparable groups. Compared to controls, oscillometry-tested children were more frequently labelled with a persistent phenotype (67% vs. 50%; adjusted OR [95% CI]: 2.34 [1.66-3.34]) with no significant difference in maintenance therapy prescription (65% vs. 58%; 1.37 [0.98-1.92]); but experienced a lower likelihood of poor control over the next year (adjusted OR [95% CI]: 0.24 [0.08-0.74]). The association between the addition of oscillometry to clinical assessment with more persistent phenotype labelling and better asthma control supports its clinical utility; no significant impact on maintenance therapy prescription was observed at the index visit.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest Bennet Desormeau and Anna Smyrnova declare no conflicts of interest. Francine Monique Ducharme has received unrestricted research funds from Astra Zeneca, Covis Pharma, GlaxoSmithKline, Merck Canada, Novartis, Teva, Trudell Medical; research funds from Covis Pharma, GlaxoSmithKline, and MEDteq in partnership with Thorasys Inc.; honorarium for consultancy work from Astra Zeneca, Covis Pharma, Teva, and Thorasys Inc.; and honorarium as an invited speaker from Covis Pharma, Jean Jean-Coutu Pharmacy and Brunet Pharmacy. Olivier Drouin has received funding from Fonds de la Recherche du Québec en Santé and research funds from Covis Pharma.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical